16,16-Dimethyl prostaglandin E2 increases survival in mice following irradiation.
16,16-Dimethyl prostaglandin E2 (DiPGE2), a stable analog of PGE2, increases the LD50/30 survival in CD2F1 male mice when given prior to ionizing radiation. Subcutaneous administration of 40 micrograms of DiPGE2 30 min prior to 60Co gamma irradiation extends the LD50/30 from 9.39 Gy in the control animals to 16.14 Gy in DiPGE2 treated, with a dose reduction factor of 1.72 [95% confidence limits: 1.62, 1.82]. The degree of protection is dependent on both the time of administration and the dose of the prostaglandin. Ten micrograms administered 5 min prior to receiving a lethal dose of 10 Gy provides 90% survival but only 10% survival if administered 30 min prior to irradiation. Experiments to determine the in vivo concentration of DiPGE2 in organs postinjection show increased levels over time, but these are not correlated with protection. At 30 min after injection, as much as 80% of the DiPGE2 present in the spleen and plasma is unmetabolized. These results suggest that the protection results from the physiologic action of DiPGE2 rather than direct in vivo detoxification of radicals.
D000818:Animals; D003037:Cobalt Radioisotopes; D004305:Dose-Response Relationship, Drug; D007279:Injections, Subcutaneous; D007928:Lethal Dose 50; D008297:Male; D051379:Mice; D011459:Prostaglandins E, Synthetic / Q000378:metabolism / Q000494:pharmacology*; D011837:Radiation-Protective Agents; D013154:Spleen / Q000378:metabolism; D013997:Time Factors; D014018:Tissue Distribution
D003037:Cobalt Radioisotopes; D011459:Prostaglandins E, Synthetic; D011837:Radiation-Protective Agents; C017244:16,16-dimethylprostaglandin E